drugset / Trial / NCT06724809
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).
Timeline
- Start
- 2025-01-16
- Primary completion
- 2026-12-07
- Completion
- 2026-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eculizumab | Monoclonal antibody | — | Intravenous |